Citations 1

Brepocitinib, Zimlovisertib, and Ropsacitinib in Hidradenitis Suppurativa

NEJM Evidence | February 9, 2024 | Volume: 3 | Issue: 3 | Pages: No page available

10.1056/evidoa2300155 | PMID 38335032